Stunning Contemporary Gem <\/p>\n
Dave Smoller co-founded Canopy Biosciences <\/p>\n
Dilip Vishwanat <\/p>\n
Canopy Biosciences, a young startup looking to accelerate the commercialization of life science medical tools and services, has exclusively licensed a gene-editing technology from Washington University in St. Louis and Johns Hopkins University. <\/p>\n
The company, which raised$2 million from investors earlier this year, was co-founded by Dave Smoller and is led by CEO and President Edward Weinstein. Smoller and Weinstein worked together at Sigma-Aldrich before the company was sold to Merck KGaA in November 2015 for $17 billion. <\/p>\n
Dave Smoller co-founded Canopy Biosciences <\/p>\n
Dilip Vishwanat <\/p>\n
Canopy looks to in-license essentially a collaboration agreement between two parties in which one company performs research and development technologies in the fields of genetic engineering and personalized medicine. <\/p>\n
The licensed technology is called Tunr and it targets translation elongation by introducing consecutive adenosine nucleotides into a gene coding sequence of interest, according to a release. <\/p>\n
<\/p>\n
Excerpt from: Stunning Contemporary Gem Dave Smoller co-founded Canopy Biosciences Dilip Vishwanat Canopy Biosciences, a young startup looking to accelerate the commercialization of life science medical tools and services, has exclusively licensed a gene-editing technology from Washington University in St. Louis and Johns Hopkins University. Continue reading
\nCanopy acquires gene-editing technology license - St. Louis Business Journal<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"